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Abstract
Background: Type III hyperlipidemia (Type III HLP) is associated with homozygosity for the ε2
allele of the APOE gene. However only about 10% of ε2 homozygotes develop Type III HLP and it
is assumed that additional genetic and/or environmental factors are required for its development.
Common variants in the LPL gene have been proposed as likely genetic co-factors.
Methods:  The frequency of the LPL SNPs D9N, N291S and S447X in 100 patients with
hyperlipidemia and APOE2/2 genotype has been determined and compared to that in healthy blood
donors and patients with hyperlipidemia.
Results: There were no statistically significant difference in the frequencies of the variants between
APOE2/2 patients and controls.
Conclusion: It is unlikely that the D9N, N291S or S447X variants in the LPL gene play an
important role in the development of Type III HLP.
Background
Type III hyperlipidemia (Type III HLP, OMIM#107741) is
a rare form of dyslipidemia characterised by elevated and
approximately equal levels of plasma triglycerides and
cholesterol and an increased risk for developing athero-
sclerosis [reviewed in [1,2]]. The great majority of sufferers
are homozygous for the ε2 allele of the apolipoprotein E
(APOE) gene. The remaining cases are the result of very
rare mutations in the APOE gene giving rise to a dominant
form of the disease and secondary factors play only a
minor role [2]. Although APOE2/2 genotype is required
for the development of Type III HLP only approximately
1–10% of APOE2/2 subjects suffer from the condition
implying that additional genetic and/or environmental
factors are necessary for its expression [1,2].
In a recent publication [3] we presented data which sug-
gests that variants in the APOA5 gene constitute an impor-
tant genetic co-factor for the development of TypeIII HLP.
Since not all Type III HLP patients were carriers of the
APOA5 SNPs it is probable that variants in other candi-
date genes are important in its development. Variants in
genes coding for proteins involved in lipolysis such as
lipoprotein lipase (LPL) have been suggested as possible
co-factors [4,5]. Additional support for LPL as a candidate
gene is provided by the suggestion that APOA5 acts as an
activator of LPL activity in vivo [6].
A large number of studies have been performed on the
association between three, functionally active single
nucleotide polymorphisms (SNPs) in the LPL gene,
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namely D9N, N291S and S447X and hyperlipidemia [7-
9]. The D9N (frequency in normal population 2–4%) and
N291S (frequency in normal population 1–7%) have
been associated in a meta-analysis with an increase in trig-
lycerides of 20% and 31% respectively [9] and might
therefore be expected to be present in increased frequency
in patients with Type III HLP. The S447X SNP (frequency
in normal population 17–22%) is associated with an 8%
decrease in triglycerides and may thus be expected to be
present at reduced frequency in patients with Type III HLP
[9]. Further evidence that variation in the LPL gene may be
a co-factor in the development of Type III HLP has been
provided by Zhang et al [4] who reported that 4 out of 17
Type III HLP patients were carriers of the LPL N291S pol-
ymorphism compared with a frequency of 3 of 230 nor-
mal lipid controls. In a small study of eight Type III HLP
patients, three were carriers of the N291S SNP neither the
D9N nor the S447X were detected although a D9N carrier
was detected in a group of three APOE2/2 normal controls
[10]. Sijbrands et al [5] determined the frequencies of the
D9N, N291S and S447X SNPs in the LPL gene in 49
probands (25 with Type III HLP) with APOE2/2 genotype.
No carriers of the D9N SNP were detected but they found
3 carriers of the N291S and 2 of the S447X SNPs. As the
authors comment, meaningful conclusions about the role
of these variants cannot be drawn due to the low numbers
and it is necessary to confirm their observations in a
larger, independently recruited group of probands.
Over a ten year period we have assembled a group of 102
patients from the lipid clinic, UKE with APOE2/2 geno-
type and hyperlipidemia giving us the opportunity to
reinvestigate the role of these LPL SNPs in the develop-
ment of Type III HLP in a larger, independently recruited
group of patients as suggested by Sijbrands et al [5]. We
have compared the frequencies of the SNPs in hyperlipi-
demic patients with APOE2/2 genotype with healthy
blood donors reasoning that if they play a role in the
development of Type III HLP then their frequencies
should be significantly different in patients compared to
an unselected, healthy population. In addition the fre-
quencies of the SNPs were determined in patients without
APOE2/2 genotype attending the lipid clinic, Universität-
sklinikum Hamburg-Eppendorf.
Methods
Patients
Patients who attended the lipid outpatient clinic, Univer-
sitätsklinikum Hamburg-Eppendorf (UKE) between 1997
and 2004 and 200 anonymous blood donors from the
Blood Transfusion Service, UKE, were included in the
study. Informed consent was obtained and the study was
approved by the local ethics committee. This patient
group has been previously described [3,11]. If clinically
allowable, at the patients first visit to the clinic any exist-
ing lipid lowering medication is discontinued and dietary
advice is given in a 60–90 minute discussion with a dieti-
cian. Six to eight weeks later the patient again attends the
clinic and it is the lipid values obtained at this visit, i.e in
the absence of lipid lowering therapy but after diet advice,
that are used in this study. Probands were unrelated and
reflect the multi-ethnic nature of the city of Hamburg and
the surrounding area. The clinical characteristics of these
patients are presented in Tables 1 and 2. There were 52
patients who were carriers of the R3500Q variant in the
APOB gene who were diagnosed as familial defective
APOB (FDB). An additional two carriers of the R3500Q
variant had APOE2/2 genotype and so were excluded
from the study. All patients with LDL above 330 mg/dl
who were not carriers of the APOB variant were catego-
rised as familial hypercholesterolemia (FH), this is suffi-
cient for a diagnosis of FH using LDL levels alone
according to the Dutch lipid clinics criteria [12].
There were 41 patients in this group which probably rep-
resents an underestimate of the number of patients with
FH since not all sufferers have such extremely high LDL
levels. Since we have insufficient family data to allow a
diagnosis in patients with LDL lower than 330 mg/dl, FH
patients with LDL below this threshold are categorised as
having hypercholesterolemia. Four hundred and thirty
four patients had hypercholesterolemia (HChol), defined
as total cholesterol (TC) above 200 mg/dl and triglycer-
ides below 150 mg/dl. Six hundred and one patients pre-
sented with a mixed hyperlipidemia (mixed HLP) defined
as total cholesterol above 200 mg/dl and triglycerides
above 150 mg/dl. This diagnosis was preferred since there
was not sufficient family data to allow a diagnosis of
familial combined hyperlipidemia. Hypertriglyceridemia
(triglycerides above 150 mg/dl and cholesterol below 200
mg/dl) was present in 89 patients and 91 probands with
cholesterol below 200 mg/dl and triglycerides below 150
mg/dl were categorised as having normal lipids. There
were 102 patients with APOE 2/2 genotype of whom two
who were also carriers of the APOBR3500Q variant and so
were not included in the study. Of the remaining 100
patients, 88 had Type III HLP based on the criteria of
ApoB/total cholesterol ratio of below 0.15 as suggested by
Blom et al [13].
Biochemical measurements
Blood samples were taken after an overnight fast. Plasma
cholesterol (TC) and triglycerides (TG) were determined
using the GPO-PAP and CHOD-PAP kits respectively from
Boehringer Mannheim. HDL was determined following
precipitation of apo B containing lipoproteins with phos-
photungstate (Boehringer Mannheim). LDL was esti-
mated using the Friedwald formula. Apoliprotein AI (Apo
AI) and Apo B were measured using the Beckmann Array
360 (Beckmann Instruments).BMC Medical Genetics 2007, 8:56 http://www.biomedcentral.com/1471-2350/8/56
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Genotyping
DNA was isolated from 10 ml blood using the QIAamp
DNA Blood Kit from Qiagen, Hilden, Germany. APOA5,
APOE and LPL polymorphisms were determined as
described [4,7,11,14].
Statistical methods
Allele frequencies were determined by gene counting and
compared using the chi-squared test. The affect of poly-
morphism on plasma lipids was analyzed using ANOVA
with genotype as group variable and age, BMI, total cho-
lesterol, triglycerides, HDL, LDL, apoB and apoAI as
dependent variables. Where appropriate values were log
transformed before analysis. A p value ≤ 0.05 was consid-
ered statistically significant. Analysis was performed using
Statistica Software.
Results
The incidence of the D9N, N291S and S447X SNPs in the
LPL gene in the different patient groups and in the blood
donors is presented in Tables 1, 2, 3. The frequency of car-
riers of the N allele of the D9N SNP in patients with
APOE2/2 genotype (0.015) was not significantly different
from either blood donors (0.03) or other patients from
the lipid clinic (0.026). Similarly there were no significant
differences in the frequency of carriers of the S allele of the
N291S SNP, 0.03 in APOE2/2 patients, 0.018 in blood
donors and 0.033 in lipid clinic patients. In the case of the
S447X SNP, there were no significant differences in the
frequency of the × allele, APOE2/2 patients 0.09, in blood
donors, 0.085, and in lipid clinic patients, 0.068. Patients
with APOE2/2 genotype were divided into those ApoB/
total cholesterol ratio of below 0.15 (n = 88) i.e consistent
with a diagnosis of Type III HLP and the remainder (n =
12). There was no statistically significant difference in the
frequencies of any of the polymorphisms when the inci-
dence between the blood donors, the lipid clinic and the
patients with Type III HLP according to this criterion were
compared (Table 3).
Table 2: Clinical characteristics of the patients with APOE2/2 
genotype
Male/Female 68/32
Age (years) 48.3 ± 11.0
BMI (kg/m2) 28.6 ± 4.2
Obese (BMI > 30) 32
CHD 17
DM2 10
ApoB (g/L)/TC (mmol/L) > 0.15 12
ApoB (g/L)/TC (mmol/L) < 0.15 88
Total cholesterol (mg/dl) 384 ± 134
Triglycerides (mg/dl) 587 ± 332
HDL (mg/dl) 43 ± 13
ApoAI (mg/dl) 140 ± 165
ApoB (mg/dl) 95 ± 40
LPL genotypes
D9N
DD 97
DN 3
NN 0
N291S
NN 94
NS 6
SS 0
S447X
SS 83
SX 16
XX 1
TC, total cholesterol
Table 1: Clinical characteristics of the patients (excluding 
APOE2/2 genotype)
Male/Female 707/601
Age (years) 45.0 ± 
13.8
BMI (kg/m2) 26.4 ± 6.4
Obese (BMI > 30) 258
CHD 168
DM2 104
Hypertriglyceridemia (TC ≤ 200 mg/dl, TG > 150 mg/
dl)
89
Mixed hyperlipidemia (TC > 200 mg/dl, TG > 150 mg/
dl)
601
Familial defective ApoB (R3500Q carrier) 52
Familial hypercholesterolemia (LDL > 330 mg/dl) 41
Hypercholesterolemia (TC > 200 mg/dl, TG ≤ 150 
mg/dl)
434
Normal (TC ≤ 200 mg/dl, TG ≤ 150 mg/dl) 91
Total cholesterol (mg/dl) 242 ± 120
Triglycerides (mg/dl) 257 ± 405
LDL (mg/dl) 148 ± 96
HDL (mg/dl) 49 ± 18
ApoAI (mg/dl) 129 ± 56
ApoB (mg/dl) 127 ± 37
APOE genotype
2/3 130
2/4 46
3/3 704
3/4 383
4/4 45
LPL genotypes
D9N
DD 1252
DN 55
NN 1
N291S
NN 1234
NS 70
SS 4
S447X
SS 1141
SX 155
XX 12
TC, total cholesterol; TG, triglyceridesBMC Medical Genetics 2007, 8:56 http://www.biomedcentral.com/1471-2350/8/56
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Patients who did not have APOE2/2 genotype were
grouped according to the form of hyperlipidemia (see
Materials and Methods) and the frequencies of the LPL
SNPs compared. Consistent with reports in the literature
the frequency of the N291S SNP was higher and that of
the S447X lower in patients with either hypertriglyceri-
demia or mixed hyperlipidemia compared to either
patients with normal lipids or the healthy blood donor
population controls. The frequency of the S allele of the
N291S determined when mixed hyperlipidemia and
hypertriglyceridemia patients were combined, 0.04, was
significantly higher than in the normal lipid controls (i.e
combined blood donor and patients with normal lipids),
0.02, p = 0.03. The frequency of the × allele of the S447X
was significantly lower, 0.047 compared to 0.078, p =
0.005. There was no significant difference in the frequency
of the D9N polymorphism between patients with elevated
triglycerides and controls. Median triglycerides were
higher in carriers of the D9N variant, 178 mg/dl com-
pared to 144 mg/dl, p = 0.02, and the N291S variant, 179
mg/dl compared to 144 mg/dl, p = 0.03 and lower in car-
riers of the S447X variant, 126 mg/dl compared to 171
mg/dl, p = 0.00004.
The frequency of the S allele of the N291S in APOE2/2
patients with Type III HLP, 0.026, lay between that of the
patients with elevated triglycerides, 0.04, and controls,
0.02, and in no case was there a statistically significant dif-
Table 3: Frequencies of LPL SNPs according to form of dyslipidemia
D9N n DD DN NN N Freq
APOE2/2 patients
ApoB (g/L)/TC (mmol/L) > 0.15 12 12 0 0 -
ApoB (g/L)/TC (mmol/L) < 0.15 88 85 3 0 0.015
Lipid clinic patients
Hypertriglyceridemia (TC ≤ 200 mg/dl, TG > 150 mg/dl) n 89 82 7 0 0.039
Mixed hyperlipidemia (TC > 200 mg/dl, TG > 150 mg/dl) n 601 575 25 1 0.022
Familial defective ApoB (R3500Q carrier) n 52 50 2 0 0.019
Familial hypercholesterolemia (LDL > 330 mg/dl) n 41 38 3 0 0.036
Hypercholesterolemia (TC > 200 mg/dl, TG ≤ 150 mg/dl) 434 420 14 0 0.016
Normal (TC ≤ 200 mg/dl, TG ≤ 150 mg/dl) n 91 87 4 0 0.022
Blood Donors 200 188 12 0 0.03
N291S n NN NS SS S Freq
APOE2/2 patients
ApoB (g/L)/TC (mmol/L) > 0.15 12 11 1 0 0.041
ApoB (g/L)/TC (mmol/L) < 0.15 88 83 5 0 0.026
Lipid clinic patients
Hypertriglyceridemia (TC ≤ 200 mg/dl, TG > 150 mg/dl) n 89 78 9 2 0.073
Mixed hyperlipidemia (TC > 200 mg/dl, TG > 150 mg/dl) n 601 560 39 2 0.036
Familial defective ApoB (R3500Q carrier) n 52 49 3 0 0.029
Familial hypercholesterolemia (LDL > 330 mg/dl) n 41 40 1 0 0.012
Hypercholesterolemia (TC > 200 mg/dl, TG ≤ 150 mg/dl) 434 421 13 0 0.015
Normal (TC ≤ 200 mg/dl, TG ≤ 150 mg/dl) n 91 86 5 0 0.027
Blood Donors 200 193 7 0 0.018
S447X n SS SX XX X Freq
APOE2/2 patients
ApoB (g/L)/TC (mmol/L) > 0.15 12 12 0 0 -
ApoB (g/L)/TC (mmol/L) < 0.15 88 71 16 1 0.092
Lipid clinic patients
Hypertriglyceridemia (TC ≤ 200 mg/dl, TG > 150 mg/dl) n 89 84 5 0 0.028
Mixed hyperlipidemia (TC > 200 mg/dl, TG > 150 mg/dl) n 601 543 56 2 0.05
Familial defective ApoB (R3500Q carrier) n 52 43 9 0 0.087
Familial hypercholesterolemia (LDL > 330 mg/dl) n 41 34 6 1 0.096
Hypercholesterolemia (TC > 200 mg/dl, TG ≤ 150 mg/dl) 434 357 69 8 0.098
Normal (TC ≤ 200 mg/dl, TG ≤ 150 mg/dl) n 91 80 10 1 0.066
Blood Donors 200 166 34 0 0.085
TC, total cholesterol; TG, triglyceridesBMC Medical Genetics 2007, 8:56 http://www.biomedcentral.com/1471-2350/8/56
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ference. The frequencies of the N allele of the D9N SNP in
patients, with Type III HLP, 0.015 were not significantly
different from those for patients with elevated triglycer-
ides, 0.025 or controls, 0.027. There was no significant
difference between the frequency if the × allele of the
S447X SNP in APOE2/2 patients, 0.09, and controls,
0.078, whereas the frequency in patients with elevated
triglycerides was significantly lower, 0.047, p = 0.01. In
Table 4 are presented the LPL genotype frequencies
according to APOE genotype. The frequency of double
carriers does not exceed that expected by chance.
Previously we reported that in these patients carriers of the
-1131T > C and S19W variants in the APOA5 gene were
more frequent in patients with Type III HLP than in con-
trols [3]. Of the three APOE2/2 patients who were carriers
of the D9N variant, two had APOA5 genotype TT/SS and
the other, TT/SW. The APOA5 genotypes of the N291S car-
riers, were three TT/SS, two TC/SS and a single TT/SW. Ten
of the S447X carriers were APOA5 TT/SS, four TT/SW, two
TC/SS and one was TC/SW. Thus APOE2/2 patients who
were carriers of the APOA5 variants were neither more nor
less likely to be carriers of a LPL SNP than non-carriers.
Discussion
Although the majority of patients with Type III HLP have
APOE genotype 2/2 only a minority of APOE2/2 subjects
develop Type III HLP implying additional genetic and/or
environmental factors are required [1,2]. The hypothesis
we wished to test in this study is that common variants in
the LPL gene may be among such additional genetic fac-
tors. This hypothesis was based on the report of Zhang et
al [4] who found a significantly increased frequency of the
N291S SNP in Type III HLP patients plus a large number
of reports in which the N291S and D9N SNPs were asso-
ciated with increased triglycerides and familial combined
hyperlipidemia whereas the S447X SNP has a lower fre-
quency in such patients [9]. If these variants are important
co-factors for the development of Type III HLP we would
expect to observe a significantly increased frequency of the
N291S and D9N SNPs and a decrease in the frequency of
the S447X SNP in patients compared to controls.
Since we failed to observe significantly altered frequencies
in any of the LPL SNPs in APOE2/2 patients compared to
controls, even under the more stringent criteria of an
apoB/total cholesterol ratio below 0.15, we conclude that
it is unlikely that these SNPs play a significant role in the
development of Type III HLP. This is in contrast to the
conclusions of Zhang et al [4] who reported for the S allele
of the N291S of 0.16 (4 carriers amongst 17 patients) in
Type III HLP compared to 0.006 (3/230) in controls. Sij-
brands et al. [5] detected 2 carriers among 25 patients with
Type III HLP but they also report a proband with APOE2/
2 genotype who was a carrier of N291S but who did not
have Type III HLP. In their study Sijbrands et al [5] did not
detect APOE2/2 probands who were carriers of the D9N
SNP, Zhang et al [4] did not investigate this variant.
As far as we are aware this is the first report investigating
the S447X SNP and Type III HLP. Since the S447X SNP is
associated with lower triglycerides it might be assumed
that it could act as a protective variant and reduce the
chance of carriers with APOE2/2 genotype from develop-
ing Type III HLP and therefore be present at a reduced fre-
quency in these patients, similarly to that observed
amongst lipid clinic patients with elevated triglycerides.
Our finding that the frequency of the S447X is similar in
Type III HLP patients as in controls shows that this is not
the case. Although our data suggest that common variants
in the LPL gene are not an important factor in the devel-
opment of Type III HLP at a population level they may
nevertheless influence the development of the condition
in APOE2/2 individuals who are carriers.
In our patient group the frequency of the N291S SNP was
increased and the S447X decreased in non-APOE2/2
patients with elevated triglycerides compared to controls
as reported in a number of studies [9], however we did not
see a significant association with the D9N SNP, the variant
with the least reported effect on triglycerides [9]. Since LPL
SNPs are associated with triglycerides in our patients who
are not APOE2/2 this implies that the triglyceride raising
effect of the N291S variant, 30%, and the lowering effect
of the S447X variant, 8%, are masked by the other genetic
and environmental factors contributing to the develop-
ment of Type III HLP in APOE2/2 patients. Consistent
with this point, we observed no statistically significant dif-
ferences in the plasma lipid values of APOE2/2 subjects
who were carriers of LPL variants and those who were not
Table 4: LPL and APOE genotypes
LPL AP
OE
S447
X
D9
N
N2
91
n 2/2 2/3 2/4 3/3 3/4 4/4
SS DD NN 1095 76 96 41 548 295 39
NS 70 6 9 1 32 20 2
S S 4 010 210
DN NN 53 1 7 2 29 13 1
N S 1 000 100
NN NN 1 0 0 0 1 0 0
S X D D N N 1 6 31 41 72 7 84 93
N S 4 000 220
D N N N 4 200 110
XX DD NN 12 1 0 0 10 1 0
N S 1 000 010
Total 1408 100 130 46 704 383 45BMC Medical Genetics 2007, 8:56 http://www.biomedcentral.com/1471-2350/8/56
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whereas for non APOE2/2 subjects the D9N and N291S
were associated with increased and the S447X with
decreased triglycerides.
The contrast between these findings and those of Zhang et
al [4] is probably due to the greater number of probands
in our study. In an earlier, small study we also reported a
high frequency of the N291S SNP in Type III HLP patients
[10]. The significance in the Zhang study is also magnified
by the low frequency in the controls, 0.007. A weakness of
our study is the relatively small number of patients, this is
due to the rareness of Type III HLP. The frequency of
APOE2/2 genotype in normal population is approxi-
mately 1% of whom 1–10% develop Type III HLP [1,2]
giving a frequency of 1–10 in 10,000 and therefore 100
probands represents the Type III HLP cases in a popula-
tion of 100.000–1.000.000, therefore in the context of
Type III HLP this is a relatively large study.
The role of multiple rare alleles in the LPL gene and the
development of Type III HLP remains to be investigated.
A high frequency of multiple rare variants in the ABCA1
gene has been reported in patients with low HDL [15].
Assuming a frequency of LPL deficiency of one in a mil-
lion, then a frequency of obligate heterozygotes for muta-
tion in the LPL gene of 0.2% is to be expected and so it
cannot be ruled out that individually rare mutations in
the LPL gene collectively play a role in the development of
Type III HLP in APOE2/2 individuals.
Conclusion
In this, to our knowledge the largest study of its kind per-
formed to date, we could not confirm the previously
reported significantly increased incidence of the N291S
SNP in LPL in Type III HLP patients. In addition we found
no association between the D9N and S447X SNPs and
Type III HLP and so we conclude that these three common
variants in the LPL gene are not an important factor in the
development of Type III HLP in probands with APOE2/2
genotype.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DE carried out the molecular genetic studies, performed
the statistical analysis, and wrote the manuscript. FB par-
ticipated in the design of the study, was responsible for
the clinical aspects and read and approved the final man-
uscript.
Acknowledgements
We thank Edda George and Christine Koop for excellent technical assist-
ance.
References
1. Mahley RW, Huang Y, Rall SC: Pathogenesis of type III hyperli-
poproteinemia (dysbetalipoproteinemia): questions, quan-
daries and paradoxes.  J Lipid Res 1999, 40:1933-1949.
2. Mahley RW, Rall SC: Type III Hyperlipoproteinemia (Dysbetal-
ipoproteinemia): The role of apolipoprotein E in normal and
abnormal lipoprotein metabolism.  In The Metabolic and molecu-
lar bases of inherited disease 8th edition. Edited by: Scriver et al.
McGraw Hill. New York; 2001:2835-2862. 
3. Evans D, Seedorf U, Beil FU: Polymorphisms in the apolipopro-
tein A5 (APOA5) gene and type III hyperlipidemia.  Clin Genet
2005, 68:369-372.
4. Zhang H, Reymer PWA, Liu MS, Forsythe IJ, Groenemeyer BE,
Frohlich J, Brunzell JD, Kastelein JJP, Hayden MR, Ma Y: Patients
with ApoE3 deficiency (E2/2, E3/2, and E4/2) who manifest
with hyperlipidemia have an increased frequency of an Asn
291  → Ser mutation in the human LPL gene.  Arterioscler
Thromb Vasc Biol 1995, 15:1695-1703.
5. Sijbrands EJG, Hoffer MJV, Meinders AE, Havekes LM, Frants RR,
Smelt AHM, De Knijff P: Severe hyperlipidemia in apolipopro-
tein E2 homozygotes due to a combined effect of hyperin-
sulinemia and an SstI polymorphism.  Arterioscler Thromb Vasc
Biol 1999, 19:2722-2729.
6. Schaap FG, Rensen PCN, Voshol PJ, Vrins C, van der Vliet HN, Cha-
muleau RAFM, Havekes LM, Groen AK, van Dijk KW: ApoAV
reduces plasma triglycerides by inhibiting very low density
lipoprotein-triglyceride (VLDL-TG) production and stimu-
lating lipoprotein lipase-mediated VLDL-TG hydrolysis.  J Biol
Chem 2004, 279:27941-27947.
7. Mailly F, Tugrul Y, Reymer PWA, Bruin T, Seed M, Groenemeyer BF,
Asplund-Carlson A, Vallance D, Winder AF, Miller GJ, Kastelein JJP,
Hamsten A, Olivecrona G, Humphries SE, Talmud P: A common
variant in the gene for lipoprotein lipase (Asp9→Asn): func-
tional implications and prevalence in normal and hyperlipi-
demic subjects.  Arterioscler Thromb Vasc Biol 1995, 15:468-78.
8. Busca R, Peinado J, Vilella E, Auwerx J, Deeb S, Vilaro S, Reina M: The
mutant Asn291ser human lipoprotein lipase is associated
with reduced catalytic activity and does not influence bind-
ing to heparin.  FEBS Lett 1995, 367:257262.
9. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG: Lipoprotein
lipase mutations, plasma lipids and lipoproteins, and risk of
ischemic heart disease: A meta-analysis.  Circulation 1999,
99(22):2901-2907.
10. Brümmer D, Evans D, Berg D, Greten H, Beisiegel U, Mann WA:
Expression of Type III hyperlipoproteinemia in patients
homozygous for apolipoprotein E-2 is modulated by lipopro-
tein lipase and postprandial hyperinsulinemia.  J Mol Med 1998,
76:355-364.
11. Evans D, Buchwald A, Beil FU: The single nucleotide polymor-
phism -1131T > C in the apolipoprotein A5 (APOA5) gene is
associated with elevated triglycerides in patients with hyper-
lipidemia.  J Mol Med 2003, 81:645-654.
12. Marks D, Thorogood M, Neil HAW, Humphries SE: A review on
the diagnosis, natural history, and treatment of familial
hypercholesterolemia.  Atherosclerosis 2003, 168:1-14.
13. Blom DJ, O'Neill FH, Marais AD: Screening for Dysbetalipopro-
teinemia by Plasma Cholesterol and Apolipoprotein B Con-
centrations.  Clin Chem 2005, 51:904-907.
14. Hixson JE, Vernier DT: Restriction isotyping of human apolipo-
protein E by gene amplification and cleavage with Hha I.  J
Lipid Res 1990, 31:545-8.
15. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs
HH: Multiple rare alleles contribute to low plasma levels of
HDL.  Science 2004, 305:869-872.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/8/56/prepub